Gelatin-based anticancer drug delivery nanosystems: A mini review

Xianchao Jiang; Zhen Du; Xinran Zhang; Fakhar Zaman; Zihao Song; Yuepeng Guan; Tengfei Yu; Yaqin Huang

doi:10.3389/fbioe.2023.1158749

Gelatin-based anticancer drug delivery nanosystems: A mini review

Front Bioeng Biotechnol. 2023 Mar 21:11:1158749. doi: 10.3389/fbioe.2023.1158749. eCollection 2023.

Authors

Xianchao Jiang¹, Zhen Du¹, Xinran Zhang¹, Fakhar Zaman¹, Zihao Song¹, Yuepeng Guan², Tengfei Yu³, Yaqin Huang¹

Affiliations

¹ Beijing Laboratory of Biomedical Materials, Beijing Key Laboratory of Electrochemical Process and Technology for Materials, Beijing University of Chemical Technology, Beijing, China.
² Beijing Key Laboratory of Clothing Materials R&D and Assessment, Beijing Engineering Research Center of Textile Nano Fiber, Beijing Institute of Fashion Technology, Beijing, China.
³ Department of Ultrasound, Beijing Tian Tan Hospital, Capital Medical University, Beijing, China.

Abstract

Drug delivery nanosystems (DDnS) is widely developed recently. Gelatin is a high-potential biomaterial originated from natural resources for anticancer DDnS, which can effectively improve the utilization of anticancer drugs and reduce side effects. The hydrophilic, amphoteric behavior and sol-gel transition of gelatin can be used to fulfill various requirements of anticancer DDnS. Additionally, the high number of multifunctional groups on the surface of gelatin provides the possibility of crosslinking and further modifications. In this review, we focus on the properties of gelatin and briefly elaborate the correlation between the properties and anticancer DDnS. Furthermore, we discuss the applications of gelatin-based DDnS in various cancer treatments. Overall, we have summarized the excellent properties of gelatin and correlated with DDnS to provide a manual for the design of gelatin-based materials for DDnS.

Keywords: anticancer; biomaterials; drug delivery; gelatin; nanosystems.

Publication types

Review

Grants and funding

This work was supported by the Fundamental Research Funds for the Central Universities (No. JD2231).